KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- Accreditation and Value-Based Care: Leveraging Operational Excellence and Clinical Services for Patients and Your Pharmacy April 24, 2024Sandra C. Canally, RN, found and CEO of the Compliance Team, discusses the goals, benefits, and opportunities of value-based care in pharmacy.
- Influenza Vaccines: Is the Quality of Evidence the Same? April 24, 2024In response to historically low flu vaccine coverage rates, Kristen Thorson, PharmD, urges pharmacists to think back to their pandemic immunization efforts and “know the power of their recommendation,” to boost public protection from influenza.
- Independent Pharmacies Must Look Out For Deceptive PBM Practices April 24, 2024A Q&A with Douglas Hoey, CEO of NCPA, on ways to change the pharmacy payment model and deceptive practices being employed by PBMs.
- Short-Term CGM for T1D More Effective Than Self-Monitoring Blood Glucose April 24, 2024Researchers’ objective was to assess the short-term glycemic benefits of continuous glucose monitoring (CGM) systems compared with patients with type 1 diabetes (T1D) who self-monitor.
- Recreational Marijuana Laws Did Not Increase Substance Use Among Adolescents April 24, 2024With more states allowing the use of recreational marijuana than ever before, researchers examined its effects among youth populations.
- In Depth Perspectives: Psychedelic Medicine, Scope Creep, And More April 24, 2024Check out these top featured stories from Drug Topics in April 2024.
- Exploring Challenges, Opportunities for Community Pharmacists in Tobacco Cessation April 24, 2024By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.
- FDA Grants Tovorafenib Approval to Treat Relapsed or Refractory Pediatric Low-Grade Glioma April 23, 2024The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.
- Smell Loss Still Impacted Some Patients 1 Year After COVID-19 Diagnosis April 23, 2024Collecting smell and taste scores from individuals with and without a history of COVID-19, researchers found significantly lower scores for smell in COVID-19-diagnosed individuals.
- FDA Issues CRL for Epidermolysis Bullosa Gene Therapy April 23, 2024Abeona Therapeutics’ pz-cel is an investigational autologous, COL7A1 gene-corrected epidermal sheet therapy for the treatment of recessive dystrophic epidermolysis bullosa.
Pharmacy Times articles
- Iptacopan Demonstrates 38.3% Proteinuria Reduction in Patients With IgAN April 24, 2024Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.
- FDA Approves Pivmecillinam for Treatment of Female Adults With Urinary Tract Infections April 24, 2024Pivmecillinam (Pivya; UTILITY therapeutics Ltd) tablets were approved for female adults with uncomplicated urinary tract infection caused by Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
- Recombinant Zoster Vaccine Demonstrates High Protection Against Shingles in Adult Patients April 24, 2024The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.
- Advocate for Greater Pharmacy Technician Roles April 24, 2024Multiple state and federal laws since the COVID-19 pandemic highlight the growing role of technicians
- Prescription Digital Therapeutics for Mental Health: Effectiveness, Challenges, and Future Trends April 24, 2024The use of artificial intelligence and real-time symptom monitoring integrate effectiveness of prescription digital therapeutics for mental health issues
- Accurate, Complete Data Entry Is Key to Medication Safety April 24, 2024Carefully checking every piece of information and proofreading for accuracy is crucial to ensure patient safety
- Optimizing Oncological Care: The Influence of AI on Insurance Approvals April 24, 2024Successful integration demands overcoming various hurdles.
- The Role of Pharmacists in Identifying and Managing Psychiatric Medication Overdoses April 24, 2024Pharmacists play a key role in psychiatric medication overdose situations
- Developing Novel Treatments for Schizophrenia: Opportunities and Challenges in Personalizing Care April 24, 2024Exploring challenges and opportunities in developing personalized treatments for schizophrenia
- Pharmacist-Led Initiatives Impact C diff-Associated Mortality, Health Care Economics April 24, 2024Laura Gillespie, PharmD, discusses some of the financial benefits of having a pharmacist focused on antimicrobial stewardship efforts in a health system.
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com